Table 5.
Comparison of Clinical and Instrumental Characteristics at Enrollment of Our Study Population and Patients Excluded From the Study Because of the Lack of Baseline Holter Monitoring Data
| Baseline Characteristics | Our Study Population (n=285) | Patients Excluded From the Study (n=183) | P Valuea |
|---|---|---|---|
| Male sex, n (%) | 202 (70.9) | 103 (56.3) | 0.001 |
| Age at diagnosis, y | 41±14 | 43±16 | 0.177 |
| LVEDD, mm | 66±10 | 61±11 | <0.001 |
| LVEF, % | 33±13 | 36±14 | 0.007 |
| Complete LBBB, n (%) | 69 (24.2) | 22 (12) | 0.004 |
| Complete RBBB, n (%) | 11 (3.9) | 5 (3) | 0.794 |
| QRS >110 ms in V1 to V3, n (%) | 102 (36.3) | 61 (36.7) | 0.924 |
| Family history of SCD/SVT/VF, n (%) | 25 (8.8) | 23 (12.6) | 0.187 |
| β‐Blocker therapy, n (%) | 252 (88.4) | 131 (71.6) | 0.103 |
| ACEI therapy, n (%) | 226 (80.1) | 131 (71.6) | 0.395 |
LVEF indicates left ventricular ejection fraction; LVEDD, left ventricular end‐diastolic diameter; LBBB, left bundle branch block; RBBB, right bundle branch block; SCD/SVT/VF, sudden cardiac death, sustained ventricular tachycardia, and ventricular fibrillation; ACEI, angiotensin‐converting enzyme inhibitor;
a
Between groups.